Abstract

Stability of 4-Aminopyridine and 3,4-Diaminopyridine Oral Capsules

Author(s): Trissel Lawrence A, Xu Quanyun A, Zhang Yanping

Issue: Mar/Apr 2002 - Dermatologic Compounding

Page(s): 155-157

Download in electronic PDF format for $75
  • Stability of 4-Aminopyridine and 3,4-Diaminopyridine Oral Capsules Page 1
  • Stability of 4-Aminopyridine and 3,4-Diaminopyridine Oral Capsules Page 2
  • Stability of 4-Aminopyridine and 3,4-Diaminopyridine Oral Capsules Page 3

Abstract

The objective of this study was to evaluate the chemical stability of 4-aminopyridine 5-mg capsules and 3,4-diaminopyridine 5-mg capsules under a variety of storage conditions. Each of the two drug preparations was extemporaneously prepared in hard gelatin capsules; lactose and micronized silica gel were used as excipients. Samples were stored under three conditions: refrigeration at 4°C and protected from light for 6 months, protected from light at room temperature that ranged from 22°C to 24°C for 6 months, and at a temperature of 37°C and protected from light for 1 month.

Once each month, visual inspection of the capsules and their powder contents was performed to identify observable changes (color, texture, etc), and the weight of the capsule content was measured individually. Chemical stability was assessed initially and at monthly intervals by means of a stability-indicating high-pressure liquid chromatography (HPLC) analytical technique based on the determination of drug content.

No visible changes were observed in any of the samples under any of the storage conditions. The hard gelatin capsules remained clear and colorless, and the content of the capsules remained an off-white powder when viewed under normal fluorescent room light. Capsule content weight did not change during the study. Both 4-aminopyridine and 3,4-diaminopyridine exhibited excellent chemical stability under all study conditions. Little or no loss of drug content occurred in either product under refrigeration, at room temperature, and even at the elevated temperature of 37°C.

The oral 5-mg capsules of 4-aminopyridine and 3,4-diaminopyridine did not undergo decomposition or other adverse changes within 6 months at refrigerated or room temperature or within 1 month of storage at 37°C.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2002
Pg. 155-157
Jan/Feb 2004
Pg. 10-14
Author(s): Preckshot John
Jul/Aug 1999
Pg. 291-294
Author(s): Allen Loyd V Jr
Jan/Feb 2004
Pg. 51
Author(s): Allen Loyd V Jr
Jan/Feb 2004
Pg. 53
Author(s): Allen Loyd V Jr
Sep/Oct 2015
Pg. 414-419
Jul/Aug 2017
Pg. 322-329
Sep/Oct 2021
Pg. 431-439
Jul/Aug 2022
Pg. 283-291
Jan/Feb 2018
Pg. 66-75
Mar/Apr 2017
Pg. 160-163
Jul/Aug 2015
Pg. 337-339
May/Jun 2016
Pg. 209-214
Author(s): Allen Loyd V Jr
Jan/Feb 2001
Pg. 9-12
Author(s): Schotik Debora
Jul/Aug 2020
Pg. 327-336
Jan/Feb 2023
Pg. 72-77
May/Jun 2016
Pg. 247-249
Author(s): Nahata Milap C
Jul/Aug 2017
Pg. 334-338
May/Jun 2018
Pg. 240-246
Jul/Aug 2016
Pg. 347-350